[1]
Muzurović E, Mikhailidis DP, Mantzoros C. Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk. Metabolism 2021; 119154770
[2]
Iacobellis G. Epicardial and pericardial fat: Close, but very different. Obesity (Silver Spring) 2009; 17: 626-7.
[3]
Muzurović EM, Vujošević S, Mikhailidis DP. Can We Decrease Epicardial and Pericardial Fat in Patients With Diabetes? J Cardiovasc Pharmacol Ther 2021; 26: 415-36.
[4]
Ansaldo AM, Montecucco F, Sahebkar A, Dallegri F, Carbone F. Epicardial adipose tissue and cardiovascular diseases. Int J Cardiol 2019; 278: 254-60.
[5]
Muzurović E, Stanković Z, Kovačević Z, Škrijelj BŠ, Mikhailidis DP. Inflammatory markers associated with diabetes mellitus - old and new players. Curr Pharm Des 2021; 27: 3020-35.
[7]
Mahabadi AA, Berg MH, Lehmann N, et al. Association of epicardial fat with cardiovascular risk factors and incident myocardial infarction in the general population: The Heinz Nixdorf Recall Study. J Am Coll Cardiol 2013; 61: 1388-95.
[8]
Nerlekar N, Brown AJ, Muthalaly RG, et al. Association of epicardial adipose tissue and high-risk plaque characteristics: A systematic review and meta-analysis. J Am Heart Assoc 2017; 6e006379
[9]
Mancio J, Azevedo D, Saraiva F, et al. Epicardial adipose tissue volume assessed by computed tomography and coronary artery disease: A systematic review and meta-analysis. Eur Heart J Cardiovasc Imaging 2018; 19: 490-7.
[10]
Sacks HS, Fain JN, Cheema P, et al. Depot-specific overexpression of proinflammatory, redox, endothelial cell, and angiogenic genes in epicardial fat adjacent to severe stable coronary atherosclerosis. Metab Syndr Relat Disord 2011; 9: 433-9.
[11]
Kitagawa T, Yamamoto H, Hattori T, et al. Tumor necrosis factor-α gene expression in epicardial adipose tissue is related to coronary atherosclerosis assessed by computed tomography. J Atheroscler Thromb 2018; 25: 269-80.
[12]
Kremen J, Dolinkova M, Krajickova J, et al. Increased subcutaneous and epicardial adipose tissue production of proinflammatory cytokines in cardiac surgery patients: Possible role in postoperative insulin resistance. J Clin Endocrinol Metab 2006; 91: 4620-7.
[13]
Baker AR, Harte AL, Howell N, et al. Epicardial adipose tissue as a source of nuclear factor-kappa B and c-Jun N-terminal kinase mediated inflammation in patients with coronary artery disease. J Clin Endocrinol Metab 2009; 94: 261-7.
[14]
Langheim S, Dreas L, Veschini L, et al. Increased expression and secretion of resistin in epicardial adipose tissue of patients with acute coronary syndrome. Am J Physiol Heart Circ Physiol 2010; 298: H746-53.
[15]
Muzurović E, Mikhailidis DP. Impact of glucagon-like peptide 1 receptor agonists and sodium-glucose transport protein 2 inhibitors on blood pressure and lipid profile. Expert Opin Pharmacother 2020; 21: 2125-35.
[16]
Savchenko LG, Digtiar NI, Selikhova LG, et al. Liraglutide exerts an anti-inflammatory action in obese patients with type 2 diabetes. Rom J Intern Med 2019; 57: 233-40.
[17]
Bonnet F, Scheen AJ. Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: The potential contribution to diabetes complications and cardiovascular disease. Diabetes Metab 2018; 44: 457-64.
